CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Annexon, Inc. - ANNX CFD

2.61
7.19%
0.05
Low: 2.49
High: 2.84
Market Trading Hours* (UTC) Open now
Closes on Tuesday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Annexon Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.78
Open* 2.84
1-Year Change* -12.62%
Day's Range* 2.49 - 2.84
52 wk Range 2.07-7.65
Average Volume (10 days) 2.25M
Average Volume (3 months) 15.94M
Market Cap 151.29M
P/E Ratio -100.00K
Shares Outstanding 53.08M
Revenue N/A
EPS -2.47
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Aug 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 26, 2023 2.78 0.71 34.30% 2.07 2.81 2.05
May 25, 2023 2.06 -0.36 -14.88% 2.42 2.44 2.04
May 24, 2023 5.15 -0.33 -6.02% 5.48 5.63 5.05
May 23, 2023 5.57 -0.22 -3.80% 5.79 6.09 5.56
May 22, 2023 5.94 0.27 4.76% 5.67 6.04 5.66
May 19, 2023 5.86 0.13 2.27% 5.73 5.97 5.67
May 18, 2023 5.76 -0.47 -7.54% 6.23 6.61 5.72
May 17, 2023 6.35 0.38 6.37% 5.97 6.40 5.78
May 16, 2023 6.00 0.06 1.01% 5.94 6.15 5.77
May 15, 2023 6.03 0.60 11.05% 5.43 6.22 5.41
May 12, 2023 5.44 -0.02 -0.37% 5.46 5.59 5.41
May 11, 2023 5.45 -0.15 -2.68% 5.60 5.67 5.38
May 10, 2023 5.59 0.20 3.71% 5.39 5.79 5.35
May 9, 2023 5.43 0.33 6.47% 5.10 5.48 4.90
May 8, 2023 5.21 0.17 3.37% 5.04 5.26 5.03
May 5, 2023 5.24 0.14 2.75% 5.10 5.38 5.07
May 4, 2023 5.17 0.23 4.66% 4.94 5.19 4.90
May 3, 2023 5.06 0.36 7.66% 4.70 5.15 4.66
May 2, 2023 4.85 -0.55 -10.19% 5.40 5.40 4.85
May 1, 2023 5.43 0.18 3.43% 5.25 5.48 5.25

Annexon, Inc. Events

Time (UTC) Country Event
Thursday, June 8, 2023

Time (UTC)

13:30

Country

US

Event

Annexon Inc Annual Shareholders Meeting
Annexon Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, June 9, 2023

Time (UTC)

16:00

Country

US

Event

Annexon Inc Annual Shareholders Meeting
Annexon Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 7, 2023

Time (UTC)

10:59

Country

US

Event

Q2 2023 Annexon Inc Earnings Release
Q2 2023 Annexon Inc Earnings Release

Forecast

-

Previous

-
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 Annexon Inc Earnings Release
Q3 2023 Annexon Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 145.599 130.713 63.469 32.328 19.112
Selling/General/Admin. Expenses, Total 33.098 30.647 14.198 7.994 3.619
Research & Development 112.501 100.066 49.271 24.524 15.528
Operating Income -145.599 -130.713 -63.469 -32.328 -19.112
Other, Net 3.652 0.385 0.048 -4.865 0.769
Net Income Before Taxes -141.947 -130.323 -63.412 -37.179 -18.303
Net Income After Taxes -141.947 -130.323 -63.412 -37.183 -18.304
Net Income Before Extra. Items -141.947 -130.323 -63.412 -37.183 -18.304
Total Extraordinary Items
Net Income -141.947 -130.323 -63.412 -37.183 -18.304
Total Adjustments to Net Income 0 -6.924 -1.095 -0.176
Income Available to Common Excl. Extra. Items -141.947 -130.323 -70.336 -38.278 -18.48
Income Available to Common Incl. Extra. Items -141.947 -130.323 -70.336 -38.278 -18.48
Diluted Net Income -141.947 -130.323 -70.336 -38.278 -18.48
Diluted Weighted Average Shares 54.6736 38.3163 16.9624 187.289 187.289
Diluted EPS Excluding Extraordinary Items -2.59626 -3.40124 -4.14658 -0.20438 -0.09867
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.59626 -3.40124 -4.14658 -0.20504 -0.09879
Unusual Expense (Income) -0.19 -0.035
Interest Income (Expense), Net Non-Operating 0.005 0.009 0.014 0.04
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 41.242 36.695 36.069 37.409 35.426
Selling/General/Admin. Expenses, Total 8.897 8.16 8.207 8.303 8.428
Research & Development 32.345 28.535 27.862 29.106 26.998
Operating Income -41.242 -36.695 -36.069 -37.409 -35.426
Other, Net 2.566 2.312 1.015 0.272 0.053
Net Income Before Taxes -38.676 -34.383 -35.054 -37.137 -35.373
Net Income After Taxes -38.676 -34.383 -35.054 -37.137 -35.373
Net Income Before Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
Net Income -38.676 -34.383 -35.054 -37.137 -35.373
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
Income Available to Common Incl. Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
Diluted Net Income -38.676 -34.383 -35.054 -37.137 -35.373
Diluted Weighted Average Shares 73.8556 72.563 68.6529 38.5844 38.5634
Diluted EPS Excluding Extraordinary Items -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 248.098 247.693 354.011 45.406 45.706
Cash and Short Term Investments 242.657 242.715 351.206 43.931 44.175
Cash & Equivalents 140.02 74.843 268.565 43.931 44.175
Prepaid Expenses 5.238 4.515 2.802 1.396 1.306
Total Assets 285.096 287.04 355.946 49.898 48.149
Property/Plant/Equipment, Total - Net 35.966 38.181 1.935 2.138 2.345
Property/Plant/Equipment, Total - Gross 38.849 38.97 3.906 3.442 3.156
Accumulated Depreciation, Total -2.883 -0.789 -1.971 -1.304 -0.811
Other Long Term Assets, Total 1.032 1.166 0 2.354 0.098
Total Current Liabilities 22.36 21.744 10.622 4.931 3.326
Accounts Payable 7.416 11.153 3.734 2.371 1.271
Accrued Expenses 14.764 10.452 6.497 2.194 1.713
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.18 0.139 0.391 0.366 0.342
Total Liabilities 53.902 55.131 11.668 6.368 5.129
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 31.542 33.387 1.046 1.437 1.803
Total Equity 231.194 231.909 344.278 43.53 43.02
Redeemable Preferred Stock 0 0 143.984 107.222
Common Stock 0.048 0.039 0.038 0.004 0.004
Additional Paid-In Capital 669.78 528.365 510.309 2.202 1.257
Retained Earnings (Accumulated Deficit) -438.262 -296.315 -165.992 -102.58 -65.397
Other Equity, Total -0.372 -0.18 -0.077 -0.08 -0.066
Total Liabilities & Shareholders’ Equity 285.096 287.04 355.946 49.898 48.149
Total Common Shares Outstanding 47.723 38.5608 38.1576 187.289 187.289
Total Receivables, Net 0 0.003 0.079 0.225
Short Term Investments 102.637 167.872 82.641
Other Current Assets, Total 0.203 0.463
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 232.536 248.098 274.777 181.372 211.254
Cash and Short Term Investments 228.165 242.657 269.519 177.594 206.659
Cash & Equivalents 144.12 140.02 210.658 104.614 112.828
Short Term Investments 84.045 102.637 58.861 72.98 93.831
Total Receivables, Net
Prepaid Expenses 4.206 5.238 5.201 3.741 4.461
Total Assets 268.778 285.096 312.722 220.704 250.569
Property/Plant/Equipment, Total - Net 35.198 35.966 36.709 37.282 37.908
Accumulated Depreciation, Total -3.419 -2.883 -2.353 -1.834 -1.295
Other Long Term Assets, Total 1.044 1.032 1.236 2.05 1.407
Total Current Liabilities 22.941 22.36 20.22 20.254 17.053
Accounts Payable 10.346 7.416 6.921 10.301 9.378
Accrued Expenses 12.211 14.764 13.129 9.789 7.486
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.384 0.18 0.17 0.164 0.189
Total Liabilities 53.917 53.902 52.12 52.66 49.955
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 30.976 31.542 31.9 32.406 32.902
Total Equity 214.861 231.194 260.602 168.044 200.614
Common Stock 0.053 0.048 0.048 0.039 0.039
Additional Paid-In Capital 691.963 669.78 664.839 537.269 532.636
Retained Earnings (Accumulated Deficit) -476.938 -438.262 -403.879 -368.825 -331.688
Other Equity, Total -0.217 -0.372 -0.406 -0.439 -0.373
Total Liabilities & Shareholders’ Equity 268.778 285.096 312.722 220.704 250.569
Total Common Shares Outstanding 53.0807 47.723 47.6265 38.6039 38.5636
Property/Plant/Equipment, Total - Gross 38.617 38.849 39.062 39.116 39.203
Other Current Assets, Total 0.165 0.203 0.057 0.037 0.134
Redeemable Preferred Stock
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -141.947 -130.323 -63.412 -37.183 -18.304
Cash From Operating Activities -116.309 -106.11 -53.087 -28.358 -17.19
Cash From Operating Activities 2.106 2.141 0.667 0.493 0.488
Non-Cash Items 19.794 18.788 4.941 7.707 0.148
Cash Taxes Paid 0 0.002 0.001
Changes in Working Capital 3.738 3.284 4.717 0.625 0.478
Cash From Investing Activities 58.443 -88.236 -83.164 -0.267 -0.017
Capital Expenditures -6.526 -1.654 -0.464 -0.267 -0.017
Cash From Financing Activities 122.908 1.795 360.876 28.395 58.456
Issuance (Retirement) of Stock, Net 130.896 1.795 363.85 30 58.456
Foreign Exchange Effects 0.001 -0.005 0.009 -0.014 -0.04
Net Change in Cash 65.043 -192.556 224.634 -0.244 41.209
Financing Cash Flow Items -7.988 0 -2.974 -1.605 0
Other Investing Cash Flow Items, Total 64.969 -86.582 -82.7
Issuance (Retirement) of Debt, Net 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -38.676 -141.947 -107.564 -72.51 -35.373
Cash From Operating Activities -32.993 -116.309 -89.17 -58.452 -30.288
Cash From Operating Activities 0.536 2.106 1.576 1.058 0.518
Non-Cash Items 3.969 19.794 14.89 9.842 4.862
Changes in Working Capital 1.178 3.738 1.928 3.158 -0.295
Cash From Investing Activities 19.517 58.443 102.058 87.96 68.251
Capital Expenditures -0.137 -6.526 -6.244 -6.075 -5.214
Other Investing Cash Flow Items, Total 19.654 64.969 108.302 94.035 73.465
Cash From Financing Activities 17.581 122.908 122.8 0.132 0.019
Financing Cash Flow Items -7.988 -7.853
Issuance (Retirement) of Stock, Net 17.581 130.896 130.653 0.132 0.019
Foreign Exchange Effects -0.005 0.001 -0.007 -0.003 0.003
Net Change in Cash 4.1 65.043 135.681 29.637 37.985
Issuance (Retirement) of Debt, Net
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Satter Management Co., L.P. Private Equity 13.2922 7056024 0 2023-03-31 MED
Bain Capital Life Sciences Investors, LLC Investment Advisor 9.2054 4886616 0 2023-03-31 LOW
Adage Capital Management, L.P. Hedge Fund 6.6875 3549975 0 2023-03-31 LOW
Redmile Group, LLC Investment Advisor/Hedge Fund 6.5993 3503190 0 2023-03-31 LOW
VR Adviser, LLC Venture Capital 6.066 3220050 0 2023-03-31 MED
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 5.7603 3057800 0 2023-03-31 LOW
Citadel Advisors LLC Hedge Fund 4.5459 2413117 -87190 2023-03-31 HIGH
Eventide Asset Management, LLC Investment Advisor 3.5175 1867250 -1759258 2023-03-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9575 1569971 21100 2023-03-31 LOW
GMT Capital Corp. Hedge Fund 2.6537 1408697 1408697 2023-03-31 MED
Millennium Management LLC Hedge Fund 2.5702 1364343 837812 2023-03-31 HIGH
Cormorant Asset Management, LP Hedge Fund 2.3548 1250000 1250000 2023-03-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.3222 1232713 0 2023-03-31 LOW
Octagon Capital Advisors LP Hedge Fund 2.2417 1190000 1190000 2023-03-31 MED
Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 2.0552 1090986 -200586 2023-03-31 MED
Invus Public Equities Advisors, LLC Investment Advisor 1.9183 1018303 1018303 2023-03-31 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 1.8838 1000000 1000000 2023-03-31 LOW
Soleus Capital Management, L.P. Hedge Fund 1.7244 915400 915400 2023-03-31 HIGH
Novartis AG Corporation 1.7157 910747 -1196497 2021-12-31 LOW
Clarus Ventures, LLC Venture Capital 1.7147 910211 0 2023-03-31

Start a global, multi-asset portfolio with an award-winning platform

Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Annexon, Inc. Company profile

About Annexon Inc

Annexon, Inc. is a clinical-stage biopharmaceutical company that is developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, which is an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases. It has completed Phase 1b safety and dose-ranging clinical trials for ANX005 and ANX007 in patients with Guillain-Barre Syndrome (GBS) and glaucoma respectively. It is also conducting clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Annexon Inc revenues was not reported. Net loss applicable to common stockholders increased 85% to $130.3M. Higher net loss reflects Research and development increase of 91% to $67.1M (expense), Compensation and personnel-related increase from $11.9M to $24.4M (expense), Compensation and personnel-related increase from $5.7M to $13.6M (expense).

Industry: Biopharmaceuticals

1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

69.89 Price
-4.330% 1D Chg, %
Long position overnight fee -0.0146%
Short position overnight fee -0.0073%
Overnight fee time 21:00 (UTC)
Spread 0.03

Gold

1,958.55 Price
+0.790% 1D Chg, %
Long position overnight fee -0.0183%
Short position overnight fee 0.0101%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.50 Price
+1.840% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00424

BTC/USD

27,687.30 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading